Characteristics | All patients | MSDT | Â | HBMT | Â | ||
---|---|---|---|---|---|---|---|
MRDneg | MRDpos | MRDneg | MRDpos | ||||
Number of patients | 339 | 85 | 14 | Â | 189 | 51 | Â |
Median age (range), years | 31 (2–60) | 41 (12–57) | 44 (5–57) | 0.457 | 27 (2–60) | 28 (9–57) | 0.151 |
Weight (range), kg | 61 (15.5–118) | 66.5 (29–97) | 68 (23–96) | 1.000 | 64 (15.5–118) | 60 (25–102) | 0.286 |
Male, n (%) | 165 (48.7%) | 41 (48.2%) | 9 (64.3%) | 0.263 | 96 (50.8%) | 19 (37.3%) | 0.086 |
Diagnosis, n (%) | Â | Â | Â | 0.264 | Â | Â | 0.031 |
 De novo AML | 333 (98.2%) | 84 (98.8%) | 13 (92.9%) |  | 188 (99.5%) | 48 (94.1%) |  |
 Secondary AML | 6 (1.8%) | 1 (1.2%) | 1 (7.1%) |  | 1 (0.5%) | 3 (5.9%) |  |
Disease status, n (%) | Â | Â | Â | 0.217 | Â | Â | 0.137 |
 CR1 | 301 (88.8%) | 81 (95.3%) | 12 (85.7%) |  | 167 (88.4%) | 41 (80.4%) |  |
 CR > 1 | 38 (11.2%) | 4 (4.7%) | 1 (14.3%) |  | 22 (11.6%) | 10 (19.6%) |  |
FLT3-ITD mutation | Â | Â | Â | 0.302 | Â | Â | 0.582 |
 Yes | 20 (5.9%) | 5 (5.9%) | 2 (14.3%) |  | 11 (5.8%) | 2 (3.9%) |  |
 No | 319 (94.1%) | 80 (94.1%) | 12 (85.7%) |  | 178 (94.2%) | 49 (96.1%) |  |
Cytogenetics | Â | Â | Â | 0.247 | Â | Â | 0.285 |
 Favorable | 59 (17.4%) | 16 (18.8%) | 1 (7.1%) |  | 30 (15.9%) | 12 (23.5%) |  |
 Intermediate | 263 (77.6%) | 65 (76.5%) | 13 (92.9%) |  | 150 (79.4%) | 35 (68.6%) |  |
 Adverse | 17 (5.0%) | 4 (4.7%) | 0 |  | 9 (4.8%) | 4 (7.8%) |  |
Conditioning regimen, n (%) | |||||||
 MA | 339 (100%) | 85 (100%) | 14 (100%) |  | 189 (100%) | 51 (100%) |  |
HLA-A-, B-, and DR-mismatched grafts, n (%) | Â | Â | Â | Â | Â | Â | 0.245 |
 0 | 101 (29.8%) | 85 (100%) | 14 (100%) |  | 1 (0.5%) | 1 (2.0%) |  |
 1 | 14 (4.1%) | 0 | 0 |  | 13 (6.9%) | 1 (2.0%) |  |
 2 | 55 (16.2%) | 0 | 0 |  | 40 (21.2%) | 15 (29.4%) |  |
 3 | 126 (49.9%) | 0 | 0 |  | 135 (71.4%) | 34 (66.7%) |  |
Donor-recipient sex-matched grafts, n (%) | Â | Â | Â | 0.249 | Â | Â | 0.481 |
 Male–male | 104 (30.7%) | 22 (25.9%) | 4 (28.6%) |  | 62 (32.8%) | 16 (31.4%) |  |
 Male–female | 86 (25.3%) | 25 (29.4%) | 1 (7.1%) |  | 55 (29.1%) | 14 (27.5%) |  |
 Female–male | 95 (28.0%) | 32 (37.6%) | 8 (57.1%) |  | 44 (23.3%) | 8 (17.6%) |  |
 Female–female | 47 (13.9%) | 6 (7.1%) | 1 (7.1%) |  | 28 (14.8%) | 12 (23.5%) |  |
Donor-recipient relationship, n (%) | Â | Â | Â | Â | Â | Â | 0.439 |
 Parent–child | 128 (37.8%) | 0 | 0 |  | 104 (55.0%) | 24 (47.1%) |  |
 Sibling–sibling | 176 (51.9%) | 85 (100%) | 14 (100%) |  | 58 (30.7%) | 19 (37.3%) |  |
 Child–parent | 32 (9.4%) | 0 | 0 |  | 24 (12.7%) | 8 (15.7%) |  |
 Other | 3 (0.9%) | 0 | 0 |  | 3 (1.6%) | 0 (0%) |  |
ABO matched grafts, n (%) | Â | Â | Â | Â | Â | Â | 0.087 |
 Matched | 201 (59.3%) | 53 (62.4%) | 9 (64.3%) | 0.345 | 104 (55.0%) | 35 (68.6%) |  |
 Major mismatch | 62 (18.3%) | 19 (22.4%) | 1 (7.1%) |  | 39 (20.6%) | 3 (5.9%) |  |
 Minor mismatch | 58 (17.1%) | 9 (10.6%) | 2 (14.3%) |  | 36 (19.0%) | 11 (21.6%) |  |
 Bi-directional mismatch | 18 (5.3%) | 4 (4.7%) | 2 (14.3%) |  | 10 (5.3%) | 2 (3.9%) |  |
EBMT score, n (%) | Â | Â | Â | 0.063 | Â | Â | 0.850 |
 0 | 0 | 0 | 0 |  | 0 | 0 |  |
 1 | 73 (21.5%) | 23 (27.1%) | 3 (21.4%) |  | 38 (20.1%) | 9 (17.6%) |  |
 2 | 156 (46.0%) | 50 (58.8%) | 7 (50.0%) |  | 78 (41.3%) | 21 (41.2%) |  |
 3 | 76 (22.4%) | 11 (12.9%) | 1 (7.1%) |  | 50 (26.5%) | 14 (27.5%) |  |
 4 | 25 (7.4%) | 1 (1.2%) | 2 (14.2%) |  | 18 (9.5%) | 4 (7.8%) |  |
 5 | 9 (2.7%) | 0 | 1 (7.1%) |  | 5 (2.6%) | 3 (5.9%) |  |
Cell compositions in allografts | |||||||
 Infused nuclear cells, (range) 108/kg | 7.51 (3.98–16.77) | 7.51 (3.98–14.75)(5.18–14.93) | 7.12 (5.78–12.75) | 0.896 | 7.40 (4.32–16.77) | 7.69 (5.4–14.07) | 0.262 |
 Infused CD34+ cells, (range) 106/kg | 2.32 (0.50–9.78) | 2.26 (0.76–9.78) | 2.05 (1.16–5.04) | 0.670 | 2.32 (0.50–9.47) | 2.46 (1.04–8.80) | 0.448 |
DLI after transplant, n (%) | |||||||
 For relapse prophylaxis and intervention | 28 (8.3%) | 6 (7.1%) | 4 (28.6%) | 0.046 | 13 (6.9%) | 5 (9.8%) | 0.686 |
 For relapse treatment | 19 (5.6%) | 2 (2.4%) | 2 (14.3%) | 0.171 | 12 (6.3%) | 3 (5.9%) | 0.902 |